| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.027 | 0.9 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |